ESC-HFA 2024: Late-Breaking Science Video Collection

Published: 14 May 2024

  • Views:

    Views Icon 1142

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024. 

Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests. 

For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

Thought-provoking discussions with the investigators.
4 sessions
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Watch now
Late-Breaker Discussion: The TITRATE-HF Study Watch now
Late-Breaker Discussion: Insights from the STEP-HFpEF Watch now
Late-Breaker Discussion: Findings from PACT-HF Watch now

Part 2

Expert Interviews

Short, practical interviews with the investigators.
8 sessions
Remote Patient Monitoring for Patients With Heart Failure: TELESAT Watch now
Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Watch now
Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Watch now
Timing of Cardio-Kidney Protection with SGLT2i Watch now
Treatment Benefit Consistency of Remote Hemodynamic Monitoring in CHF: MONITOR-HF Subgroup Analysis Watch now
Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF Watch now
FINE-HEART: Design & Baseline Characteristics Watch now
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device Watch now

About the episode

HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).

RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure who had been treated with guideline-directed drug and device therapies were enrolled in the trial. Participants were randomized 1:1 to recieve either the V-Wave inter-atrial shunt, or were included in the control arm.

Interview Questions:

  1. What is the importance of this study?
  2. Could you tell us more about the V-Wave inter-atrial shunt system?
  3. What was the patient population and study design?
  4. What are your key findings?
  5. What are the key take-home messages for clinicians?
  6. What further study is still needed, and what are the next steps?

Recorded onsite at HFA 2024, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance, Mirjam Boros
Video Specialist: Tom Green
Interviewer: Jonathan McKenna

Faculty Biographies

Stefan Anker

Stefan Anker

Professor of Cardiology

Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.

Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.